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INTRODUCTION
Posttransplantation lymphoproliferative disorder (PTLD) is a 
serious complication following solid organ transplantation. Most 
of PTLD is related to an interaction of Epstein-Barr virus (EBV) 
infection and immune suppression.
1,2 PTLD occurs most 
common after intestine transplantation and the least common 
after renal transplantation.
3,4 PTLD can involve any organs. 
Abdominal organs are frequently involved, and up to 50% of all 
cases of PTLD are confined to the abdomen.
5 The disease 
manifestation and the anatomic pattern of organ involvement is 
highly dependent on the type of transplantation. 
To provide more detailed understanding of hepatic 
involvement of PTLD, here a case of PTLD involving liver 
after renal transplantation is presented with radiological 
imaging findings. A review about classification and clinical 
considerations and the imaging features of PTLD involving 
liver will be discussed. Familiarity with the imaging 
findings of this disorder can help early and accurate 
diagnosis and result in better prognosis.
CASE SUMMARY
A 17-year-old male was admitted with the complaint of 
generalized abdominal pain. He had history of end stage 
renal disease due to focal segmental glomerulosclerosis. 
He got kidney transplantation 6 years ago. Kidney donor 
was his mother. He had also history of acute rejection 
immediately after kidney transplantation, and managed with 
plasmapheresis and immunosuppresion. He was managed 
with drugs including Tacrolimus (Prograf
®, Astellas, Tokyo, 
Japan), mycophenolate mofetil (Cellcept
®, Roche, Basel, 
Switzerland), and Deflazacort (Calcort
®, Sanofi-aventis, 
Paris, France) for six years with gradual dose reduction.
He complained generalized abdominal pain for three 
days, and visited hospital. He presented symptoms such as 
fever and night sweating, but no weight loss, dizziness, 
dyspnea, anorexia, nausea, vomiting, diarrhea or other 
abdominal symptoms were presented. He presented physical 
examination findings including hepatomegaly with three 
finger width and mild abdominal distension. 
The laboratory findings showed hemoglobin 8.5 g/dL, 
white blood cell count 8,500/mm
3, (neutrophil 63.2%, 
lymphocyte 22.1%), platelet count 284,000/mm
3. Biochemical 
tests showed that the serum level of alanine aminotran-
sferase was 24 IU/L, aspartate aminotransferase was 45 
IU/L, and alkaline phosphatase was 99 IU/L. Serum protein 
was 5.7 g/dL and albumin was 2.9 g/dL. Total bilirubin was 
0.5 mg/dL. Blood urea nitrogen (BUN) was 20 mg/dL and 
creatinine was 1.3 mg/dL. Serum amylase was elevated as 
590 U/L, but lipase was 22 U/L. Lactate dehydrogenase was 
1,612 IU/L and β-2 Microglobulin was elevated to 6.6 µg/mL. 
Alpha-fetoprotein was less than 1 ng/mL. Hepatitis B surface 
(HBs) antigen and anti-HBs were negative.166  The Korean Journal of Hepatology Vol. 17. No. 2, June 2011
  
  
Figure 1. Initial contrast-enhanced abdominal CT scan of a 17-year old male. (A) There were multiple low attenuated mass in liver. 
There were also homogenous attenuated tumor mass in right cardiophrenic area (arrow) and right pleural effusion. (B) CT scan of 
another level showed also multiple hepatic mass. (C) CT scan below showed large mesenteric mass (asterisk) with central heterogenous 
low attenuated area filling in peritoneal cavity. Native kidneys were atrophic due to end stage renal disease (arrows). (D) CT scan 
in pelvis level showed transplanted kidney in right side. Diffuse infiltrative mesenteric mass with homogenous attenuation encased 
mesenteric vessels (arrows).
Contrast-enhanced abdomen CT was taken. There were 
multiple, well-defined, homogenously low attenuated round 
masses in liver (Fig. 1A and B). Mass size was up to 2.5 cm. 
Also there were multiple mesenteric mass over 10 cm 
(Fig. 1C and D). It showed heterogenous enhancement and 
partial central necrotic low attenuation area. The mesenteric 
mass showed encasement of mesenteric vessels and thickening 
of adjacent bowel wall. Ultrasonography showed multiple 
well-defined homogenous low echoic masses in liver 
(Fig. 2).
Fludexoyglucose positron emission tomography (FDG-PET) 
scan showed multiple hypermetabolic lesions in supra-
clavicular area, mediastinal area, liver, mesentery, peritoneum, 
and multiple bones (Fig. 3).
Percutaneous fine-needle-aspiration biopsy was performed 
in right lobe mass under ultrasound guidance. Histologic 
examination of the biopsy specimen showed post trans-
plantation lymphoprolifertive disease, monomorphic type 
(diffuse large B cell lymphoma). Special staining results 
were as follows: CD20 (+), CD10 (+), bcl-6 (+), CD3 (-), 
CD5 (-), CD56 (-), CD1a (-), TdT (-), EBV (-). Ki-67 
labeling index was 60%. 
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Figure 2. Ultrasonography showed multiple homogeneously low 
echoic mass in liver.
   
Figure 4. CT scan taken at three months later after systemic chemotherapy. (A) Most of hepatic mass disappeared. (B) CT scan at 
the same level with Fig. 1C showed that most of mesenteric mass also disappeared. There is small residual shrunken mass around 
mesenteric root (arrow). (C) CT scan at the same level with Fig. 1D also showed that there is no residual mass around mesenteric 
vessels.
Figure 3. FDG-PET scan showed multiple hypermetabolic areas 
in chest, abdomen and bones.
After pathological diagnosis was confirmed, administration 
of mycophenolate mofetil discontinued and, R-CHOP 
chemotherapy started. After three months with chemotherapy 
of four cycles, follow up CT scan was taken. CT scan 
showed markedly decreased mass in liver and mesentery 
(Fig. 4A-C). He is alive until now without recurrence after 
30 months follow up. 
DISCUSSION
PTLD is known as a serious complication of solid organ 
transplantation following with immunosuppression. Develo-
pment of lymphoma after transplantation was first described 
by Doak et al
6 in a renal transplant recipient in 1968, whereas 
the term post-transplant lymphoproliferative disorder or 
disease was introduced by Starzl et al in 1984.
7
An important risk factor for PTLD development is the 
intensity and the amount of immunosuppression administered 
to the patient.
1 Another risk factor is EBV-seronegative 
patients receiving allografts from EBV-seropositive donors, 
consequently leading to primary EBV infection. This is also 
the main reason for the higher incidences of PTLD observed 
in pediatric transplant recipients.
1 PTLD are related to 
infection from EBV, but the presence of this virus is not 
essential for the diagnosis. EBV-negative PTLD is also 
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recognized as in this case presented above. This type of 
PTLD tends to develop much later after transplantation and 
has a significantly worse outcome when compared with 
EBV-positive PTLD.
1,2 
Society of Hematology and the World Health Organization 
generated the current classification system, which identifies 
four major categories: 1) hyperplastic (or early) lesions; 2) 
polymorphic (generally monoclonal) lesions; 3) monomorphic 
(ie, lymphomatous invariably monoclonal) lesions, which 
are further subcategorized along recognized lines of 
B-cell, T-cell, or natural killer cell neoplasia; and 4) other 
lymphoproliferative disorders, including Hodgkin lymphoma.
8 
Most cases develop PTLD within 1 year after the 
transplantation, although some cases develop several years 
later. PTLD occurs in up to 5% of transplantation recipient 
patients, depending on the type of organ transplanted and 
the type and duration of immunosuppressive treatment.
5 
Allograft involvement by PTLD was more frequent in lung 
and liver transplant recipients that in kidney and heart 
transplantation.
3 The incidence varies with allograft type, 
with reported frequencies following transplant of intestines 
up to 20%, heart 2-10%, lung 4-8% liver 2-8% and kidneys 
1%.
4 However, as many thousands of renal transplants are 
performed each year, the majority of PTLD are observed in 
kidney transplant recipients.
1 The abdominal cavity is 
frequently involved by PTLD, with abdominal disease being 
seen in 50-75% of patients with PTLD.
3,9 Extranodal 
involvement (80% of cases) is more common than nodal 
involvement (20%) in intraabdominal disease.
3 Liver is the 
most frequently involved abdominal solid organ, with 
involvement seen in 30-45% of post-liver transplantation 
PTLD, 40% of post-pancreas transplantation PTLD, 23% of 
post-heart transplantation PTLD and 10% of post-lung 
transplantation PTLD.
9 In another large collaborative study, 
liver involvement was seen in 22%, 9%, 5%, and 5% of 
cases of monomorphic PTLD (non-Hodgkin lymphoma) 
following liver, heart, lung or lung-heart, and kidney 
transplantation, respectively.
10
Imaging findings of PTLD have much in common with 
those of lymphoma. Especially imaging features of PTLD 
have much in common with those of lymphoma related to 
acquired immunodeficiency syndrome (AIDS), in that 
extranodal involvement was seen in more than 80% of 
AIDS-related lymphoma, similar to the frequency of 
extranodal disease among PTLD patients.
3,9 However, CT 
manifestation of non-Hodgkin lymphoma in general population 
and PTLD in transplant recipients have important difference 
that extranodal disease occurs only 25% of non-Hodgkin 
lymphoma.
3,5
CT findings of hepatic involvement of PTLD includes (in 
descending order of frequency of occurrence) 1) discrete 
low-attenuation nodular lesions, ranging from 1 to 4 cm, 
which has reduced enhancement compared with the normal 
liver parenchyma in the portal venous phase (Fig. 1A and B), 
2) ill-defined infiltrative or geographic pattern, which has 
poorly-marginated but can be identified against a normally 
enhancing background liver and can resemble focal fatty 
infiltration, 3) a heterogeneous mass at porta hepatis, which 
can directly extend into the biliary tree or gallbladder, with 
resultant hepatomegaly or biliary obstruction.
3,9,11 On 
ultrasonography, these hepatic lesions appear hypoechoic 
(Fig. 2) and they can be confused with liver abscesses on 
ultrasound.
11,12
PTLD can involve other abdominal organs. Splenic 
involvement is less common, manifesting as focal masses 
with or without splenomegaly.
11,12 Imaging findings of 
hollow viscus involvement also resemble those of lymphoma, 
although ulceration and perforation is more common in 
PTLD.
11,13 It presents with localized circumferential wall 
thickening, aneurismal dilatation of involved loops, luminal 
excavation or ulceration, eccentric polypoid mass, extrumural 
extention and intussusceptions.
3 Extranodal involvement of 
peritoneum and abdominal wall can produce diffuse soft- 
tissue infiltration or discrete lobulated mass.
3 The case 
presented above showed discrete multiple liver mass and 
both types of peritoneal involvement (Fig. 1A-D). PTLD can 
affect both native and transplanted kidneys and may 
manifest as focal renal masses or diffuse infiltration.
3,5
In the cases of thoracic involvement, the most frequent 
imaging finding is nodules with a peripheral and basal 
predominance. And other findings include air space con-
solidation, mediastinal lymphadenopathy, pleural or chest 
wall masses, pericardial or pleural effusions.
5 Intracerebral 
PTLD is usually isolated and has similar imaging features to 
AIDS-related cerebral lymphoma.
5,14 The characteristic 
finding is of a cerebral nodule demonstrating hemorrhage, 
necrosis and peripheral enhancement. Lesions are most 
commonly seen in the periventricular and subcortical white 
matter. Biopsy may be required to distinguish between 
PTLD and other disorders such as atypical infection.
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FDG-PET scanning proved superior efficacy compared 
with conventional CT scanning for staging as well as 
treatment evaluation.
1  PET scan can be an effective imaging 
method for early detection and diagnosis of PTLD.
Treatment of PTLD always consists of reduction of 
immunosuppression. In addition, monoclonal antibody 
therapy and antiviral therapies are frequently applied, and 
systemic chemotherapy is applied in the case of non-response 
group. Distinguishing between the polymorphic and mono-
morphic subtypes is important for treatment planning 
because the former will often respond to immunomodulation 
alone, however this distinction is not reliably made on the 
basis of imaging studies, tissue acquisition is necessary. 
Tissue confirmation is also required to differentiate between 
PTLD and rejection.
SUMMARY
PTLD is a serious and still frequently observed complication 
of solid organ transplantation. Liver is frequently involved 
organ, and well-defined multiple mass are most frequently 
seen.
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